In the Matter of BioCoral, Inc., GC China Turbine Corp., Race World International, Inc., and Worldwide Biotech & Pharmaceutical Co.; Order of Suspension of Trading, 35691 [2015-15374]

Download as PDF Federal Register / Vol. 80, No. 119 / Monday, June 22, 2015 / Notices is one-half hour. Accordingly, the staff estimates that total annual burden for all participants is 5 hours (10 × one-half hour). The Commission staff estimates that compliance staff work at subject entities results in an internal cost of compliance, at an estimated hourly wage of $283, of $141.50 per year per entity (.5 hours × $283 per hour = $141.50 per year). Therefore, the aggregate annual internal cost of compliance is approximately $1,415 ($141.50 × 10= $1,415). Written comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission’s estimates of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted in writing within 60 days of this publication. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information under the PRA unless it displays a currently valid OMB control number. Please direct your written comments to: Pamela Dyson, Director/Chief Information Officer, Securities and Exchange Commission, c/o Remi PavlikSimon, 100 F Street, NE., Washington, DC 20549, or send an email to: PRA_ Mailbox@sec.gov. Dated: June 16, 2015. Brent J. Fields, Secretary. [FR Doc. 2015–15173 Filed 6–19–15; 8:45 am] BILLING CODE 8011–01–P SECURITIES AND EXCHANGE COMMISSION tkelley on DSK3SPTVN1PROD with NOTICES [ File No. 500–1] In the Matter of BioCoral, Inc., GC China Turbine Corp., Race World International, Inc., and Worldwide Biotech & Pharmaceutical Co.; Order of Suspension of Trading June 18, 2015. It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of BioCoral, Inc. (CIK No. 919605), a Delaware VerDate Sep<11>2014 17:45 Jun 19, 2015 Jkt 235001 corporation with its principal place of business listed as La Garenne-Colombes, France, with stock quoted on OTC Link (previously, ‘‘Pink Sheets’’) operated by OTC Markets Group, Inc. (‘‘OTC Link’’) under the ticker symbol BCRA, because it has not filed any periodic reports since the period ended September 30, 2012. On February 27, 2014, the Division of Corporation Finance sent BioCoral a delinquency letter requesting compliance with its periodic filing obligations, but the letter was returned because of BioCoral’s failure to maintain a valid address on file with the Commission. It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of GC China Turbine Corp. (CIK No. 1380528), a revoked Nevada corporation with its principal place of business listed as Wuhan, China, with stock quoted on OTC Link under the ticker symbol GCHT, because it has not filed any periodic reports since the period ended September 30, 2011. On or about October 15, 2013, GC China Turbine received a delinquency letter sent by the Division of Corporation Finance requesting compliance with their periodic filing obligations. It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Race World International, Inc. (CIK No. 1415736), a revoked Nevada corporation with its principal place of business listed as Weifang, China, with stock quoted on OTC Link under the ticker symbol RCWR, because it has not filed any periodic reports since the period ended June 30, 2011. On July 22, 2013, Race World International received a delinquency letter sent by the Division of Corporation Finance requesting compliance with their periodic filing obligations. It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of Worldwide Biotech & Pharmaceutical Co. (CIK No. 95302), a forfeited Delaware corporation with its principal place of business listed as Xi’an, China, with stock quoted on OTC Link under the ticker symbol WWBP, because it has not filed any periodic reports since the period ended March 31, 2011. On May 10, 2012, the Division of Corporation Finance sent Worldwide Biotech a delinquency letter requesting compliance with their periodic filing obligations, but the letter was returned because of Worldwide Biotech’s failure to maintain a valid address on file with the Commission. PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 35691 The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed companies. Therefore, it is ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed companies is suspended for the period from 9:30 a.m. EDT on June 18, 2015, through 11:59 p.m. EDT on July 1, 2015. By the Commission. Jill M. Peterson, Assistant Secretary. [FR Doc. 2015–15374 Filed 6–18–15; 4:15 pm] BILLING CODE 8011–01–P SECURITIES AND EXCHANGE COMMISSION Proposed Collection; Comment Request Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of FOIA Services, 100 F Street NE., Washington, DC 20549–2736. Extension: Voluntary XBRL-Related Documents, SEC File No. 270–550, OMB Control No. 3235–0611. Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.) (‘‘Paperwork Reduction Act’’), the Securities and Exchange Commission (the ‘‘Commission’’) is soliciting comments on the collection of information summarized below. The Commission plans to submit this existing collection of information to the Office of Management and Budget (‘‘OMB’’) for extension and approval. As part of our evaluation of the potential of interactive data tagging technology, the Commission permits registered investment companies (‘‘funds’’) to submit on a voluntary basis specified financial statement and portfolio holdings disclosure tagged in eXtensible Business Reporting Language (‘‘XBRL’’) format as an exhibit to certain filings on the Commission’s Electronic Data Gathering, Analysis and Retrieval System (‘‘EDGAR’’). The current voluntary program permits any fund to participate merely by submitting a tagged exhibit in the required manner. These exhibits are publicly available but are considered furnished rather than filed. The purpose of the collection of information is to help evaluate the usefulness of data tagging and XBRL to registrants, investors, the Commission, and the marketplace. E:\FR\FM\22JNN1.SGM 22JNN1

Agencies

[Federal Register Volume 80, Number 119 (Monday, June 22, 2015)]
[Notices]
[Page 35691]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-15374]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[ File No. 500-1]


In the Matter of BioCoral, Inc., GC China Turbine Corp., Race 
World International, Inc., and Worldwide Biotech & Pharmaceutical Co.; 
Order of Suspension of Trading

June 18, 2015.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
BioCoral, Inc. (CIK No. 919605), a Delaware corporation with its 
principal place of business listed as La Garenne-Colombes, France, with 
stock quoted on OTC Link (previously, ``Pink Sheets'') operated by OTC 
Markets Group, Inc. (``OTC Link'') under the ticker symbol BCRA, 
because it has not filed any periodic reports since the period ended 
September 30, 2012. On February 27, 2014, the Division of Corporation 
Finance sent BioCoral a delinquency letter requesting compliance with 
its periodic filing obligations, but the letter was returned because of 
BioCoral's failure to maintain a valid address on file with the 
Commission.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
GC China Turbine Corp. (CIK No. 1380528), a revoked Nevada corporation 
with its principal place of business listed as Wuhan, China, with stock 
quoted on OTC Link under the ticker symbol GCHT, because it has not 
filed any periodic reports since the period ended September 30, 2011. 
On or about October 15, 2013, GC China Turbine received a delinquency 
letter sent by the Division of Corporation Finance requesting 
compliance with their periodic filing obligations.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Race World International, Inc. (CIK No. 1415736), a revoked Nevada 
corporation with its principal place of business listed as Weifang, 
China, with stock quoted on OTC Link under the ticker symbol RCWR, 
because it has not filed any periodic reports since the period ended 
June 30, 2011. On July 22, 2013, Race World International received a 
delinquency letter sent by the Division of Corporation Finance 
requesting compliance with their periodic filing obligations.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Worldwide Biotech & Pharmaceutical Co. (CIK No. 95302), a forfeited 
Delaware corporation with its principal place of business listed as 
Xi'an, China, with stock quoted on OTC Link under the ticker symbol 
WWBP, because it has not filed any periodic reports since the period 
ended March 31, 2011. On May 10, 2012, the Division of Corporation 
Finance sent Worldwide Biotech a delinquency letter requesting 
compliance with their periodic filing obligations, but the letter was 
returned because of Worldwide Biotech's failure to maintain a valid 
address on file with the Commission.
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of the above-listed companies.
    Therefore, it is ordered, pursuant to Section 12(k) of the 
Securities Exchange Act of 1934, that trading in the securities of the 
above-listed companies is suspended for the period from 9:30 a.m. EDT 
on June 18, 2015, through 11:59 p.m. EDT on July 1, 2015.

    By the Commission.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2015-15374 Filed 6-18-15; 4:15 pm]
BILLING CODE 8011-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.